Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy

被引:330
作者
Taylor, AL [1 ]
Watson, CJE [1 ]
Bradley, JA [1 ]
机构
[1] Univ Cambridge, Dept Surg, Addenbrookes Hosp, Cambridge CB2 2QQ, England
关键词
immunosuppression; solid organ transplant;
D O I
10.1016/j.critrevonc.2005.03.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Effective immunosuppression is an essential pre-requisite for successful organ transplantation and improvements in outcome after transplantation have to a large extent been dependent on developments in immunosuppressive therapy. Here we provide an overview of the different immunosuppressive agents currently used in solid organ transplantation. A historical perspective on the development of immunosuppression for organ transplantation is followed by a review of the individual agents, with a focus on their mechanism of action and efficacy. Steroids, anti-proliferative agents (azathioprine and mycophenolate), calcineurin inhibitors (cyclosporine and tacrolimus) and TOR inhibitors (sirolimus and everolimus) are discussed along with both polyclonal and monoclonal antibody preparations. Many of the key clinical trials that underpin current clinical usage of these agents are described and side-effects of the different agents are highlighted. Finally, a number of newer agents still in various stages of clinical development are briefly considered. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:23 / 46
页数:24
相关论文
共 222 条
[91]   Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial [J].
Kelly, D ;
Jara, P ;
Rodeck, B ;
Lykavieris, P ;
Burdelski, M ;
Becker, M ;
Gridelli, B ;
Boillot, O ;
Manzanares, J ;
Reding, R .
LANCET, 2004, 364 (9439) :1054-1061
[92]  
Keown P, 1996, TRANSPLANTATION, V61, P1029
[93]  
KLINTMALM GBG, 1993, TRANSPLANT P, V25, P641
[94]   Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation [J].
Klupp, J ;
Bechstein, WO ;
Pratschke, J ;
Tullius, SG ;
Gebhard, A ;
Lobeck, H ;
Langrehr, JM ;
Neuhaus, R ;
Neuhaus, P .
TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) :1443-1444
[95]   Campath-1H in renal transplantation: The University of Wisconsin experience [J].
Knechtle, SJ ;
Fernandez, LA ;
Pirsch, JD ;
Becker, BN ;
Chin, LT ;
Becker, YT ;
Odorico, JS ;
D'Alessandro, AM ;
Sollinger, HW .
SURGERY, 2004, 136 (04) :754-759
[96]   Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study [J].
Knechtle, SJ ;
Pirsch, JD ;
Fechner, JH ;
Becker, BN ;
Friedl, A ;
Colvin, RB ;
Lebeck, LK ;
Chin, LT ;
Becker, YT ;
Odorico, JS ;
D'Alessandro, AM ;
Kalayoglu, M ;
Hamawya, MM ;
Hu, HZ ;
Bloom, DD ;
Sollinger, HW .
AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (06) :722-730
[97]   Sirolimus and mycophenolate mofetil after liver transplantation [J].
Kniepeiss, D ;
Iberer, F ;
Grasser, B ;
Schaffellner, S ;
Tschetiessnigg, KH .
TRANSPLANT INTERNATIONAL, 2003, 16 (07) :504-509
[98]   CONTINUOUS CULTURES OF FUSED CELLS SECRETING ANTIBODY OF PREDEFINED SPECIFICITY [J].
KOHLER, G ;
MILSTEIN, C .
NATURE, 1975, 256 (5517) :495-497
[99]   Disposition and immunodynamics of basiliximab in liver allograft recipients [J].
Kovarik, J ;
Breidenbach, T ;
Gerbeau, C ;
Korn, A ;
Schmidt, AG ;
Nashan, B .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (01) :66-72
[100]   Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation [J].
Kovarik, JM ;
Kahan, BD ;
Rajagopalan, PR ;
Bennett, W ;
Mulloy, LL ;
Gerbeau, C ;
Hall, ML .
TRANSPLANTATION, 1999, 68 (09) :1288-1294